{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.9","upperLimit":"6.9","value":"4.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"}],"units":"Participants"}],"description":"PFS was defined as the time (in months) between the date of randomization and the date of first documented disease progression or death, whichever occurs first. Disease progression was determined based on investigator assessment using modified RECIST criteria. PD: at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.","id":"OG000","title":"Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"ITT population for efficacy analyses included all randomized participants, regardless of whether they received any study drug. In the efficacy analyses, the ITT population, participants were grouped according to the treatment arm to which they were assigned. The data was planned to be reported for Atezolizumab arm only","reportingStatus":"POSTED","timeFrame":"From the time of randomization to the date of death due to any cause or up to data cut off date: 08 May 2015 (up to 21 months)","title":"PFS (Modified RECIST)","type":"SECONDARY","unitOfMeasure":"months"}